KTTA - Pasithea Therapeutics rockets 132% after adding esketamine nasal spray to U.K. offerings

Pasithea Therapeutics (NASDAQ:KTTA) soars 132% premarket after announcing that its wholly owned subsidiary, Pasithea Clinics, has been approved to provide esketamine nasal spray (Spravato) for treatment-resistant depression in adults, and has begun offering the treatment in its Knightsbridge, London location. Only three clinics in the U.K. have been accredited to offer this treatment. “Esketamine is safe and effective, especially when combined with ongoing psychiatric support,” said Dr. Yassine Bendiabdallah, Managing Director of Pasithea Clinics in U.K. Spravato (esketamine) CIII nasal spray is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate receptor – an ionotropic glutamate receptor. It has a novel mechanism of action than currently available therapies for major depressive disorder (MDD).

For further details see:

Pasithea Therapeutics rockets 132% after adding esketamine nasal spray to U.K. offerings